Systematic review and meta-analysis

pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis

S Bek, A B Bojesen, J V Nielsen, J Sode, S Bank, U Vogel, V Andersen

Publikation: Bidrag til tidsskriftReviewForskningpeer review

106 Downloads (Pure)

Resumé

Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects ~1% of the Caucasian population. Over the last decades, the availability of biological drugs targeting the proinflammatory cytokine tumour necrosis factor α, anti-TNF drugs, has improved the treatment of patients with RA. However, one-third of the patients do not respond to the treatment. We wanted to evaluate the status of pharmacogenomics of anti-TNF treatment. We performed a PubMed literature search and all studies reporting original data on associations between genetic variants and anti-TNF treatment response in RA patients were included and results evaluated by meta-analysis. In total, 25 single nucleotide polymorphisms were found to be associated with anti-TNF treatment response in RA (19 from genome-wide association studies and 6 from the meta-analyses), and these map to genes involved in T cell function, NFκB and TNF signalling pathways (including CTCN5, TEC, PTPRC, FCGR2A, NFKBIB, FCGR2A, IRAK3). Explorative prediction analyses found that biomarkers for clinical treatment selection are not yet available.The Pharmacogenomics Journal advance online publication, 13 June 2017; doi:10.1038/tpj.2017.26.

OriginalsprogEngelsk
TidsskriftPharmacogenomics Journal
Vol/bind17
Sider (fra-til)403–411
ISSN1470-269X
DOI
StatusUdgivet - 2017

Fingeraftryk

Pharmacogenetics
Meta-Analysis
Genome-Wide Association Study
PubMed
Single Nucleotide Polymorphism
Publications
Research Design
Tumor Necrosis Factor-alpha
Pharmaceutical Preparations
Population

Citer dette

@article{ed1efa82a1654d739b360d299248edab,
title = "Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis",
abstract = "Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects ~1{\%} of the Caucasian population. Over the last decades, the availability of biological drugs targeting the proinflammatory cytokine tumour necrosis factor α, anti-TNF drugs, has improved the treatment of patients with RA. However, one-third of the patients do not respond to the treatment. We wanted to evaluate the status of pharmacogenomics of anti-TNF treatment. We performed a PubMed literature search and all studies reporting original data on associations between genetic variants and anti-TNF treatment response in RA patients were included and results evaluated by meta-analysis. In total, 25 single nucleotide polymorphisms were found to be associated with anti-TNF treatment response in RA (19 from genome-wide association studies and 6 from the meta-analyses), and these map to genes involved in T cell function, NFκB and TNF signalling pathways (including CTCN5, TEC, PTPRC, FCGR2A, NFKBIB, FCGR2A, IRAK3). Explorative prediction analyses found that biomarkers for clinical treatment selection are not yet available.The Pharmacogenomics Journal advance online publication, 13 June 2017; doi:10.1038/tpj.2017.26.",
author = "S Bek and Bojesen, {A B} and Nielsen, {J V} and J Sode and S Bank and U Vogel and V Andersen",
year = "2017",
doi = "10.1038/tpj.2017.26",
language = "English",
volume = "17",
pages = "403–411",
journal = "The Pharmacogenomics Journal",
issn = "1470-269X",
publisher = "Nature Publishing Group",

}

Systematic review and meta-analysis : pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis. / Bek, S; Bojesen, A B; Nielsen, J V; Sode, J; Bank, S; Vogel, U; Andersen, V.

I: Pharmacogenomics Journal, Bind 17, 2017, s. 403–411.

Publikation: Bidrag til tidsskriftReviewForskningpeer review

TY - JOUR

T1 - Systematic review and meta-analysis

T2 - pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis

AU - Bek, S

AU - Bojesen, A B

AU - Nielsen, J V

AU - Sode, J

AU - Bank, S

AU - Vogel, U

AU - Andersen, V

PY - 2017

Y1 - 2017

N2 - Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects ~1% of the Caucasian population. Over the last decades, the availability of biological drugs targeting the proinflammatory cytokine tumour necrosis factor α, anti-TNF drugs, has improved the treatment of patients with RA. However, one-third of the patients do not respond to the treatment. We wanted to evaluate the status of pharmacogenomics of anti-TNF treatment. We performed a PubMed literature search and all studies reporting original data on associations between genetic variants and anti-TNF treatment response in RA patients were included and results evaluated by meta-analysis. In total, 25 single nucleotide polymorphisms were found to be associated with anti-TNF treatment response in RA (19 from genome-wide association studies and 6 from the meta-analyses), and these map to genes involved in T cell function, NFκB and TNF signalling pathways (including CTCN5, TEC, PTPRC, FCGR2A, NFKBIB, FCGR2A, IRAK3). Explorative prediction analyses found that biomarkers for clinical treatment selection are not yet available.The Pharmacogenomics Journal advance online publication, 13 June 2017; doi:10.1038/tpj.2017.26.

AB - Rheumatoid arthritis (RA) is a chronic inflammatory disease that affects ~1% of the Caucasian population. Over the last decades, the availability of biological drugs targeting the proinflammatory cytokine tumour necrosis factor α, anti-TNF drugs, has improved the treatment of patients with RA. However, one-third of the patients do not respond to the treatment. We wanted to evaluate the status of pharmacogenomics of anti-TNF treatment. We performed a PubMed literature search and all studies reporting original data on associations between genetic variants and anti-TNF treatment response in RA patients were included and results evaluated by meta-analysis. In total, 25 single nucleotide polymorphisms were found to be associated with anti-TNF treatment response in RA (19 from genome-wide association studies and 6 from the meta-analyses), and these map to genes involved in T cell function, NFκB and TNF signalling pathways (including CTCN5, TEC, PTPRC, FCGR2A, NFKBIB, FCGR2A, IRAK3). Explorative prediction analyses found that biomarkers for clinical treatment selection are not yet available.The Pharmacogenomics Journal advance online publication, 13 June 2017; doi:10.1038/tpj.2017.26.

U2 - 10.1038/tpj.2017.26

DO - 10.1038/tpj.2017.26

M3 - Review

VL - 17

SP - 403

EP - 411

JO - The Pharmacogenomics Journal

JF - The Pharmacogenomics Journal

SN - 1470-269X

ER -